The company have significantly advanced its development of a novel solution for ATTR-CM, utilizing the investigational drug. Initial patient results suggests potential benefits for patients diagnosed with a serious https://biotech250799.bluxeblog.com/74594406/bridgebio-advances-attr-cm-therapy-through-attruby